We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(ESMO Breast 2021 Virtual) May 7, 2021 - First results from a phase II study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021, held 5 to 8 May, demonstrated clinical benefit in patients with metastatic invasive lobular breast cancer (ILC), particularly in patients with triple negative ILC.
(University of Arizona) May 5, 2021 - Recently published research from the University of Arizona Health Sciences shows that advanced-stage kidney cancer is more common in Hispanic Americans and Native Americans than in non-Hispanic whites, and that both Hispanic Americans and Native Americans in Arizona have an increased risk of mortality from the disease.
(MedPage Today) May 6, 2021 - Two commonly used thiotepa-based conditioning regimens were associated with favorable outcomes among patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT), according to a retrospective observational study.
(USC News) May 7, 2021 - USC Clinical Trials will soon start a clinical trial to determine the safety and effectiveness of investigational medications to treat acute myeloid leukaemia in patients who have relapsed or are not responsive to standard treatment options.
(Yahoo! Finance) May 7, 2021 - Tessa Therapeutics Ltd. today announced that early clinical data from a Phase 1 dose-escalation study of Tessa’s TT11X allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy in patients with CD30-positive lymphoma will be featured in a podium presentation at the ASGCT 24th Annual Meeting, held virtually from May 11 – 14, 2021.
(AstraZeneca) May 7, 2021 - POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). Positive high-level results from the final analysis of POSEIDON showed the combination of Imfinzi, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.
(CRISPR Therapeutics) May 6, 2021 - CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Nkarta, Inc., a biopharmaceutical company developing engineered NK cell therapies to treat cancer, today announced a strategic partnership to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. Under the agreement, the companies will co-develop and co-commercialize two CAR NK cell product candidates, one targeting the CD70 tumor antigen and the other target to be determined.
(Wall Street Journal) May 6, 2021 - Illumina spun off Grail to develop a test for 50 forms of the disease. Regulators seek to block our reunion. The Federal Trade Commission is jeopardizing our chance to save more lives from cancer. In March the FTC filed a lawsuit to block Illumina from reuniting with Grail, a company we spun off with our technology and staffed with our employees and in which we retained an ownership share.
(ESMO Breast 2021 Virtual) May 7, 2021 - Functional homologous repair deficiency (HRD), as defined by a RAD51-low score, emerged as an indicator of patient outcome and response to carboplatin in triple negative breast cancer (TNBC) or PARP inhibitors, according to findings from two studies presented at the ESMO Breast Cancer Virtual Congress 2021, held 5 to 8 May.
(ESMO) May 6, 2021 - Findings from the final analysis of the TITAN study in patients with metastatic castration-sensitive prostate cancer.